Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24208321 | 0.94 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL24208539 | 0.94 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL30391504 | 0.94 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL24208374 | 0.90 | ALDH1A1 (0.44) | ALDH1A1POLBSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL24208601 | 0.90 | ALDH1A1 (0.44) | ALDH1A1POLBSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL24208486 | 0.88 | SMN1; SMN2 (0.50) | ALDH1A1POLBSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL24208327 | 0.85 | AAK1 (0.47) | ALDH1A1POLBSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL24208367 | 0.84 | ALDH1A1 (0.46) | ALDH1A1POLBSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL24208399 | 0.84 | ALDH1A1 (0.43) | ALDH1A1POLBSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL24208413 | 0.84 | TGM2 (0.48) | ALDH1A1MAPTKMT2AMEN1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2022140403-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140397-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140387-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140410-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | ALDH1A1 4735/4885POLB 953/4885SMN1; SMN2 2644/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4654/4885POLB 430/4885SMN1; SMN2 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.